Business
Nuwellis Announces Presentation of Aquadex®-Related Abstracts at the 2022 Pediatric Academic Societies Meeting
New Data Adds to the Growing Body of Research Supporting the Negative Impact of Fluid Overload, Therapies to Prevent Kidney Injury and the Use of
About this update from Nuwellis, Inc.
[{"type":"text","content":"New Data Adds to the Growing Body of Research Supporting the Negative Impact of Fluid Overload, Therapies to Prevent Kidney Injury and the Use of Ultrafiltration for Varying Patient Populations\nMINNEAPOLIS, May 09, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced the presentation of three Aquadex-related abstracts at the annual Pediatric Academic Societies (PAS) meeting. This research was funded in part by unrestricted grants by Nuwellis to the University of Alabama at Birmingham (UAB). Other sources of funding included the Nuwellis-funded Ultrafiltration Therapy Registry using Aquadex – Pediatric (ULTRA-Peds) and the National Kidney Collaborative (NKC). PAS, the premier national meeting for pediatric research, was held in Denver, Colorado from April 21-25, 2022. “We are excited to add to the ever-growing body of research supporting the negative impact of fluid excess and the benefits of Aquadex,” said Nestor Jaramillo, Jr., President and CEO of Nuwellis. “I’m grateful to the leader of these projects, Dr. David Askenazi, for his thoughtful research on the benefits of ultrafiltration for pediatric patients.” Aquadex SmartFlow® ultrafiltration enables gentle, precise, and adjustable fluid removal, helping achieve the desired fluid balance with only 35 mL (around 2.5 tablespoons) of blood outside of the body. The customizable rate of fluid removal is particularly important for pediatric patients, who have a small amount of blood in their bodies. Aquadex is cleared by the FDA for use in adults and pediatric patients weighing 20 kg (44 lbs.) or more. “Ultrafiltration using the Aquadex system provides an easy to use, safe and effective therapy for managing fluid balance in pediatric patients,” said Dr. Askenazi. “I’m grateful for the commitment from the company and I’m proud to partner with Nuwellis to provide meaningful data that helps the medical community determine when and how to implement Aquadex for those who suffer from pediatric kidney disease.” About NuwellisNuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on developing, manufacturing, and commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minnea...